Trials / Completed
CompletedNCT04719546
Risk Factors of Necrotizing Enterocolitis in Premature Newborns
Identifying Risk Factors of Necrotizing Enterocolitis in the NICU of Nancy Benchmarking With the NICU of Lyon Over 10 Years
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 459 (actual)
- Sponsor
- Central Hospital, Nancy, France · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
With premature newborn increase survival, the risk of serious neonatal morbidity, such as necrotizing enterocolitis (NEC), also increased. NEC affects between 2 to 7% of premature infants including 5 to 22% of newborns weighing less than 1000 g. NEC is an acquired disease, caused by inflammation of the intestinal lining. It is the most common life-threatening gastrointestinal emergency of prematurity, associated with a significant morbidity and mortality. The etiology and physiopathology are multifactorial, complex, and remain poorly understood. The mechanism of the lesions seems to involve factors including immaturity of the intestinal barrier and the immune system, microvascular imbalance, disturbed gut flora and systemic inflammation. Despite improved knowledge about this disease, the proportion of surviving patients has not improved for several years. It frequently leads to long-term sequelae depending on the severity of the NEC and its treatment. Early diagnosis and early treatment of NEC may reduce the risk of mortality and morbidity. The aim of this retrospective bi-centric study is to look for risk factors allowing the prediction of NEC in order to prevent and improve the early management of this disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observation of related perinatal factors | Data described in Primary outcome measures will be collected in both groups |
Timeline
- Start date
- 2021-01-21
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
- First posted
- 2021-01-22
- Last updated
- 2022-03-04
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04719546. Inclusion in this directory is not an endorsement.